A number of reports have described an essential role for the activation of the JNK/c-Jun pathway in the apoptotic and antiproliferative response to sorafenib, despite the controversy pertaining c-Jun function in cell cycle progression and HCC initiation14–17. Here, JUN is linked to hepatocellular carcinoma.